Connect Biopharma is trading at $1.62, down -20.62%, amid broader risk-off conditions and weakness in smaller biotech shares.

  • The Nasdaq Composite is down 1.20%, while premarket technology weakness is weighing on smaller biotech shares.
  • No new company-specific announcement was identified for September 14, 2026.
  • Management is scheduled to present at the H.C. Wainwright conference on September 15; H.C. Wainwright reiterated a Buy rating and $7.00 price target.